Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Sells 22,223 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh sold 22,223 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of C$9.32, for a total value of C$207,029.47.

Adrian J. Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian J. Haigh purchased 22,222 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Price Performance

Fennec Pharmaceuticals stock opened at C$12.80 on Thursday. The stock has a market capitalization of C$346.11 million, a price-to-earnings ratio of -12.55 and a beta of 0.35. Fennec Pharmaceuticals Inc. has a 52-week low of C$9.27 and a 52-week high of C$15.43. The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 3.29. The stock’s 50 day moving average price is C$13.50 and its two-hundred day moving average price is C$12.74.

Fennec Pharmaceuticals (TSE:FRX) last issued its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The company had revenue of C$13.25 million for the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. On average, equities analysts predict that Fennec Pharmaceuticals Inc. will post 0.4202312 earnings per share for the current year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.